SCHEMBL29615418

SCHEMBL29615418

Cn1cc(-c2ccc(CNc3ccncn3)cc2)cn1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 12/20 0.51
▸ MKNK1 Q9BUB5 1/20 0.48
▸ IRAK1 P51617 1/20 0.47
▸ IRAK4 Q9NWZ3 1/20 0.47
▸ LCK P06239 1/20 0.45
▸ CSF1R P07333 1/20 0.45
▸ PDGFRB P09619 1/20 0.45
▸ PDGFRA P16234 1/20 0.45
▸ FLT3 P36888 1/20 0.45
▸ CLK1 P49759 2/20 0.42
▸ WNT1 P04628 2/20 0.42
▸ GSK3B P49841 2/20 0.42
▸ DYRK1A Q13627 2/20 0.42
▸ CCNK O75909 1/20 0.41
▸ CDK12 Q9NYV4 1/20 0.41
▸ JAK1 P23458 1/20 0.41
▸ JAK3 P52333 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29868714 1.00 KIT (0.51) KITMKNK1IRAK1IRAK4LCK
SCHEMBL29614332 0.80 MKNK1 (0.47) KITMKNK1
SCHEMBL22918752 0.80 KIT (0.56) KITMKNK1LCKCSF1RPDGFRB
SCHEMBL29614113 0.80 KIT (0.56) KITMKNK1LCKCSF1RPDGFRB
SCHEMBL29868735 0.79 KIT (0.52) KITMKNK1
SCHEMBL28862430 0.78 KIT (0.52) KITLCKCSF1RPDGFRBPDGFRA
SCHEMBL34464686 0.75 CCNC (0.44) MKNK1CSF1RWNT1GSK3BDYRK1A
SCHEMBL16522694 0.74 KDM4E (0.61) CLK1GSK3BDYRK1A
SCHEMBL7132304 0.74 CXCR4 (0.50) DYRK1A
SCHEMBL22918645 0.72 KIT (0.51) KITMKNK1LCKCSF1RPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220267320-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2022-08-25 — — US claimed
US-20260109697-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2026-04-23 — — US disclosed
CN-118955500-A 4- (Imidazo [1,2-a ] pyridin-3-yl) -pyrimidine derivatives 默克专利股份公司 2024-11-15 — — CN disclosed
US-20220267320-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2022-08-25 — — US disclosed
CN-114174293-A 4- (imidazo [1,2-a ] pyridin-3-yl) -pyrimidine derivatives 默克专利股份公司 2022-03-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109697-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES CHUK, CNKSR1, KIT KIT 3/4885MKNK1 1238/4885IRAK1 373/4885
US-20220267320-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES NCOA3, NCOR1, NCOA4 KIT 273/4885MKNK1 1025/4885IRAK1 1414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback